Nrx Pharmaceuticals Inc (NRXP) Stock Price, Quote & News

Company Profile

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-f...

Industry: Biotechnology

Sector: Healthcare

Phone: 484 254 6134

Website: www.nrxpharma.com

Address:

1201 Orange Street, Suite 600, Wilmington, United States

Siddy_Sauce Jul. 5 at 7:45 AM

$NRXP thanks

1 · Reply

Siddy_Sauce Jul. 4 at 11:34 AM

$NRXP more than a breakout once FDA news lands

0 · Reply

AIIAAIIA_88 Jul. 4 at 11:02 AM

$NRXP I must be nuts but still see the even more bullish chart pointing to a big breakout soon! JMO

1 · Reply

alwaysWinVlmr Jul. 3 at 11:34 PM

$NRXP @the_franz gonna read this time, short expert? Or gonna "resist"? Resist harder.

1 · Reply

Siddy_Sauce Jul. 3 at 4:03 PM

$NRXP what’s that got to do with NrXP? - thanks

3 · Reply

Outcomes Jul. 3 at 3:15 PM

$NRXP https://www.pharmather.com/news/pharmather-announces-path-to-ketamine-commercialization-with-no-planned-financing-confirms-fda-approval-goal-date-of-august-9th-2025-for-ketamine

0 · Reply

TheRealBomb Jul. 3 at 2:44 PM

$NRXP Happy Independence Day Eve! Hoping the fireworks tomorrow and next week will be awesome. Peace yall.

0 · Reply

alwaysWinVlmr Jul. 3 at 12:14 PM

$NRXP @the_franz Why are you suddenly so active, you short expert? @larumba is deleted, and now you start spamming? If you truly believe in what you say, then you better sell. Unless you don't want to. Unless you want others to sell. But not you. You apparently will "hold" and keep telling others to sell, right?

1 · Reply

the_franz Jul. 3 at 7:42 AM

$NRXP By the way, it was August 2023 when the last insider (apart from @JavittMDd) bought something - for those who haven't looked. Not a single one of the so-called honest shareholders has a plausible answer other than "they can do what they want with their money". Because it fits in incredibly well: the co-founder and chairman of ATAI was involved in this week's $50M placement. He doesn't care because he's a billionaire, I realize that, but it's about the signal. It's about showing the market that the company can be trusted. August 2023! 2 years! Not a single dollar has flowed into NRx from insiders since then! You're telling me that's normal for a company with $31 PT? These are all millionaires for sure. They could show the market that they trust the company and the path it's taking with a laughable $50K - and they don't. They don't care about the company, as long as the compensation is right. They don't care about you, but yes, keep pressing the "Bullish" button. 🤣

2 · Reply

dontfeedthebashers Jul. 3 at 4:23 AM

$NRXP

0 · Reply

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Agreement to Acquire Interest in Cohen and Associates, LLC for HOPE's Network of Interventional Psychiatry Clinics

Jun 23, 2025, 8:03 AM EDT - 12 days ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of Commissioner's National Priority Voucher Application for Intravenous Ketamine (NRX-100)

Jun 16, 2025, 8:03 AM EDT - 19 days ago

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics, Inc. Announce Strategic Investor Relations Partnership with astr partners

Jun 12, 2025, 8:03 AM EDT - 23 days ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics, Inc. to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Jun 5, 2025, 8:03 AM EDT - 4 weeks ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Abbreviated New Drug Application (ANDA) for Preservative-Free IV Ketamine

May 16, 2025, 8:46 PM EDT - 7 weeks ago

NRx Pharmaceuticals, Inc. (NRXP) Q1 2025 Earnings Call Transcript

May 15, 2025, 4:03 PM EDT - 7 weeks ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 15, 2025, 10:15 AM EDT - 7 weeks ago

HOPE Therapeutics, Inc. a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Signing of Term Sheet for $7.8 Million Debt Financing to Fuel HOPE Clinic Acquisitions

May 13, 2025, 8:03 AM EDT - 7 weeks ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals (NASDAQ:NRXP) Announce Signing of Definitive Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the HOPE Network of Interventional Psychiatry Clinics

May 12, 2025, 8:03 AM EDT - 7 weeks ago

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report First Quarter 2025 Financial Results on May 15, 2025

May 6, 2025, 8:03 AM EDT - 2 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Investor Event at Mar-A-Lago Club on May 8, 2025

May 5, 2025, 8:03 AM EDT - 2 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Patent Application for NRX-100, its Proprietary, Preservative Free Formulation of IV Ketamine

Apr 30, 2025, 8:46 AM EDT - 2 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces FDA Award of Filing Fee Waiver for Upcoming NRX-100 (preservative free ketamine) New Drug Application to Treat Patients with Suicidal Depression

Apr 21, 2025, 8:01 AM EDT - 2 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc.to Participate in an H.C. Wainwright @ Home Fireside Discussion on Tuesday, April 22, 2025

Apr 3, 2025, 8:03 AM EDT - 3 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of a Term Sheet for Strategic Investment from a Global Medical Device Manufacturer into HOPE

Mar 31, 2025, 8:02 AM EDT - 3 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Definitive Purchase Agreement with Dura Medical; Initial Acquisition for Planned International Network of Interventional Psychiatry Clinics

Mar 24, 2025, 8:02 AM EDT - 3 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Letter of Intent with Neurospa TMS Holdings, LLC for Expansion of its Planned International Network of Interventional Psychiatry Clinics

Mar 17, 2025, 10:50 AM EDT - 3 months ago

NRx Pharmaceuticals, Inc. (NRXP) Q4 2024 Earnings Call Transcript

Mar 17, 2025, 8:02 AM EDT - 3 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 12, 2025, 8:01 AM EDT - 4 months ago

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 17, 2025

Feb 6, 2025, 8:03 AM EST - 5 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025

Feb 3, 2025, 8:59 AM EST - 5 months ago

HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Engage BTIG as Financial Advisor

Jan 28, 2025, 8:05 AM EST - 5 months ago

HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Execute Agreement for $27 Million Funding Transaction for HOPE Clinic Acquisition

Jan 28, 2025, 8:03 AM EST - 5 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Advances Relationship with Anson Funds with $8.9 Million Financing, Including Above the Market Equity and Senior Secured Debt

Jan 21, 2025, 8:02 AM EST - 5 months ago

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Regains Compliance With Nasdaq Minimum Market Value of Listed Securities Requirement

Jan 15, 2025, 8:02 AM EST - 6 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces the Appointment of Michael Taylor to its Board of Directors and Appointment of Anita Nunes as Board Observer; Ms. Nunes to be Appointed Director of HOPE Therapeutics, Inc.

Jan 14, 2025, 8:03 AM EST - 6 months ago

HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Alert Investors to Sanjay Gupta/CNN Program on Ketamine, Featuring Kadima Neuropsychiatry Institute Founder Dr. David Feifel

Jan 13, 2025, 8:04 AM EST - 6 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces it has Filed an Application with NASDAQ to Uplist to the NASDAQ Global Market from the NASDAQ Capital Market

Jan 8, 2025, 10:20 AM EST - 6 months ago

Central Nervous System (CNS) Therapeutics Market Forecast (2025-2035) by Disease, Drug Class, Distribution Channel and Region

Jan 7, 2025, 8:07 AM EST - 6 months ago

HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Dr. Jonathan Javitt and Dr. David Feifel to Present Keynote Address, Beyond Ketamine Monotherapy: Combined Interventional Treatment of Suicidal Depression and PTSD, at the 8th Annual Neuroscience Innovation Forum in San Francisco

Jan 6, 2025, 10:16 AM EST - 6 months ago

HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Term Sheet for $27 Million in Funding for HOPE Clinic Acquisitions and Pharmaceutical Operations

Jan 6, 2025, 8:03 AM EST - 6 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announce Dura Medical as the Expected Initial Florida Acquisition for its Planned International Network of Interventional Psychiatry Clinics

Jan 2, 2025, 8:03 AM EST - 6 months ago

Hope Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Kadima Neuropsychiatry Institute as the Expected First Acquisition for its International Network of Interventional Psychiatry Clinics

Dec 30, 2024, 8:03 AM EST - 6 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression

Nov 26, 2024, 8:03 AM EST - 7 months ago

NRx Pharmaceuticals (NASDAQ: NRXP) Announces Participation in the NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference December 3-4, 2024

Nov 25, 2024, 8:03 AM EST - 7 months ago

NRx Pharmaceuticals (NASDAQ:NRXP) Announces Publication of Paper Entitled "Quality Assurance of Depression Ratings in Psychiatric Clinical Trials"

Nov 18, 2024, 7:51 PM EST - 8 months ago

NRx Pharmaceuticals, Inc. (NRXP) Q3 2024 Earnings Call Transcript

Nov 18, 2024, 4:05 PM EST - 8 months ago

NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial Officer

Nov 14, 2024, 4:05 PM EST - 8 months ago

NRx Pharmaceuticals (NASDAQ:NRXP) Reports Third Quarter and Year to Date 2024 Financial Results and Provides Business Update

Nov 13, 2024, 8:03 AM EST - 8 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Conference Call to Discuss Third Quarter and Year to Date 2024 Financial Results to November 18, 2024

Nov 7, 2024, 4:06 PM EST - 8 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter and Year to Date 2024 Financial Results on November 14, 2024

Oct 30, 2024, 7:47 AM EDT - 8 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire its First Florida Interventional Psychiatry Clinics

Oct 3, 2024, 6:55 AM EDT - 9 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire a Premier West Coast Interventional Psychiatric Clinic

Sep 30, 2024, 7:00 AM EDT - 9 months ago

NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announces Completion of Twelve Months of Stability on the First Manufactured Commercial Scale Lot of NRX-100 (Ketamine)

Sep 11, 2024, 7:55 AM EDT - 10 months ago

NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Featured on Psychiatrist.com

Sep 3, 2024, 7:55 AM EDT - 10 months ago

NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) and HOPE Therapeutics, Inc. Announce Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024

Aug 26, 2024, 7:55 AM EDT - 11 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics

Aug 15, 2024, 2:39 PM EDT - 11 months ago

NRx Pharmaceuticals, Inc. (NRXP) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 4:01 PM EDT - 11 months ago

NRx Pharmaceuticals (NASDAQ:NRXP) Reports Second Quarter and Year to Date 2024 Financial Results and Provides Business Update

Aug 13, 2024, 4:01 PM EDT - 11 months ago

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Second Quarter and Year to Date 2024 Financial Results on August 14, 2024

Siddy_Sauce Jul. 5 at 7:45 AM

$NRXP thanks

1 · Reply

Siddy_Sauce Jul. 4 at 11:34 AM

$NRXP more than a breakout once FDA news lands

0 · Reply

AIIAAIIA_88 Jul. 4 at 11:02 AM

$NRXP I must be nuts but still see the even more bullish chart pointing to a big breakout soon! JMO

1 · Reply

alwaysWinVlmr Jul. 3 at 11:34 PM

$NRXP @the_franz gonna read this time, short expert? Or gonna "resist"? Resist harder.

1 · Reply

Siddy_Sauce Jul. 3 at 4:03 PM

$NRXP what’s that got to do with NrXP? - thanks

3 · Reply

Outcomes Jul. 3 at 3:15 PM

$NRXP https://www.pharmather.com/news/pharmather-announces-path-to-ketamine-commercialization-with-no-planned-financing-confirms-fda-approval-goal-date-of-august-9th-2025-for-ketamine

0 · Reply

TheRealBomb Jul. 3 at 2:44 PM

$NRXP Happy Independence Day Eve! Hoping the fireworks tomorrow and next week will be awesome. Peace yall.

0 · Reply

alwaysWinVlmr Jul. 3 at 12:14 PM

1 · Reply

the_franz Jul. 3 at 7:42 AM

2 · Reply

dontfeedthebashers Jul. 3 at 4:23 AM

$NRXP

0 · Reply

Siddy_Sauce Jul. 2 at 9:24 PM

$NRXP do you really want to be sat there when the news drops?

0 · Reply

Siddy_Sauce Jul. 2 at 8:41 PM

$NRXP take note followers, add me for big wins. This has to climb due to FDA compliance. Do not miss out!

1 · Reply

systemish Jul. 2 at 6:55 PM

$NRXP Always with the .33 cents

0 · Reply

Siddy_Sauce Jul. 2 at 5:36 PM

$NRXP when a company announces that a significant development take note! Get in now before it starts climbing before lift off at FDA approval. Ignore at your peril

1 · Reply

Idiot_Trader_ Jul. 2 at 4:29 PM

$NRXP Is Wong still around?

2 · Reply

TheRealBomb Jul. 2 at 1:06 PM

$NRXP https://mailchi.mp/nrxpharma.com/nrx-pharmaceuticals-publishes-shareholder-update-letter-july22025?e=8d1aabdd13

0 · Reply

Lunatics Jul. 2 at 12:15 PM

$NRXP https://www.nrxpharma.com/management-answers-to-shareholder-questions/

0 · Reply

DavidBG Jul. 2 at 10:22 AM

$NRXP The ANDA submission was announced on June 5 (https://ir.nrxpharma.com/2025-06-05-NRx-Pharmaceuticals,-Inc-NASDAQ-NRXP-Files-Abbreviated-New-Drug-Application-ANDA-for-Preservative-Free-IV-Ketamine). The FDA should acknowledge receipt and give notice of priority review within sixty days (https://www.fda.gov/media/153631/download, p. 12), meaning by August 4, so in a little over a month from now. An answer is due eight months after submission. (The FDA already went through the Module III and had very few questions, which have already been addressed, so I'm hoping for an early response, but best to stick to official timelines.) And then comes drug revenue, in addition to revenue from clinics that have been acquired to that date. Dr. Javitt already said that one manufacturer had submitted a licensing offer for NRX-100. I wonder whether any other companies have gotten in touch with offers since then.

1 · Reply

the_franz Jul. 2 at 7:54 AM

$NRXP And once again, I urge everyone to visit EDGAR and check out the insider purchases. If no one around the company trusts the company, why are you damn retards hitting the "Bullish" button? Why do you trust the company more than the BoD does, which is living very well off your money, while all the longs here are deep red? I don't get it. We have a $31 PT, the insiders here should be filing Form 4 until they go broke. We should all send the idiots to hell - yeah well, if the share structure would allow it. And yes, I'm pissed because I was hoping for a small, steady pump at the end of H1 to get out with a 60%-70% loss - 50% would be ideal, but we'll never see the >$10 needed for it because this fucking company just can't get anything done.

1 · Reply

the_franz Jul. 2 at 7:41 AM

$NRXP 🤣 Yes, NRx has a unique position. Namely that of not having delivered anything materially positive since the end of the pandemic compared to the competition (Compass, atai, also Cybin, possibly Mindmed and hey, Big Pharma is also still around). They had a head start in which NRX-100 and NRX-101 could have been something of a bridge until said companies come to market with novel treatments. The window for this idea is just getting smaller and smaller. And they still don't deliver. It's H2, for fuck's sake!

1 · Reply

alwaysWinVlmr Jul. 1 at 10:25 PM

$NRXP Here is what I think (not that anybody asked :) ) Everything is my personal opinion, feel free to object. NRXP still needs money to pay off Ansons, to fund their operations and to aquire clinics. They wrote before in SEC filingd that they will sell shares at the market to raise 20MM dollars. And then also get some offerings. Right now NRXP can't sell - as soon as they start - retail will sell too, and there will be noone who would buy. Also - if NRXP sells at current price - they would need to sell 30% of outstanding shares. They can't do that. The catalyst is shifted - till thereis news, if NRXP can use the voucher or not. If not- then NRXP just files the regular NDA, like they wanted to do previously. It wouldn't cost them anything. So IMO one way or the other, the catalyst will happen. What happens to the price? The price may go down. Continue shake out, retail is not needed for big boys, except when they want retail to create liquidity for when they sell. CONTINUE IN COMMENTS

1 · Reply

Lunatics Jul. 1 at 10:24 PM

$NRXP "The combination of regulatory positioning, clinical backing, and public health alignment puts NRx in a unique position to compete in a sector undergoing both supply disruption and therapeutic evolution." - PNW

0 · Reply

Market Cap	58.44M
Revenue (ttm)	0.00
Net Income (ttm)	-25.13M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	93,800
Avg Vol	294,440
Day's Range	N/A - N/A
Shares Out	17.29M
Stochastic %K	76%
Beta	1.59
Analysts	Strong Sell
Price Target	$31.67